Alpha 2.0
Login Register
» Authors » Charles Comins

Charles Comins

Explore the profile of Charles Comins including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 202
Followers 0
Related Specialties
Oncology
Pharmacology
General Medicine
Top 10 Co-Authors
Alfredo Addeo
Hayley McKenzie
David J Pinato
Nick A Maskell
Judith Cave
Alessio Cortellini
William Hollingworth
Gloria Barone
Nicola Mills
Carmel Conefrey
Published In
BMJ Open
Front Oncol
Br J Surg
Radiother Oncol
Br J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinical and patient-reported outcomes in women offered oncoplastic breast-conserving surgery as an alternative to mastectomy: ANTHEM multicentre prospective cohort study
Davies C, Johnson L, Conefrey C, Mills N, Fairbrother P, Holcombe C, et al.
Br J Surg . 2024 Dec; 112(1). PMID: 39718969
Background: Oncoplastic breast-conserving surgery may be a better option than mastectomy, but high-quality comparative evidence is lacking. The aim of the ANTHEM study (ISRCTN18238549) was to explore clinical and patient-reported...
2.
Understanding decision-making for and against oncoplastic breast-conserving surgery as an alternative to a mastectomy in early breast cancer: UK ANTHEM qualitative study
Davies C, Conefrey C, Mills N, Fairbrother P, Holcombe C, Whisker L, et al.
Br J Surg . 2024 Jun; 111(6). PMID: 38877844
Background: Oncoplastic breast-conserving surgery may allow women with early breast cancer to avoid a mastectomy, but many women undergo more extensive surgery, even when breast-conserving options are offered. The aim...
3.
Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an mutation in tissue: a UK pilot study
Brooks H, Li L, Addeo A, Stevens M, Comins C, Oltean S
Front Oncol . 2023 Jul; 13:1197037. PMID: 37476385
The development of methodologies to analyse circulating tumour DNA (ctDNA) in the blood or urine of cancer patients provides an invaluable resource that can be used for diagnosis and prognosis...
4.
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis
Anpalakhan S, Huddar P, Behrouzi R, Signori A, Cave J, Comins C, et al.
Front Oncol . 2023 Jun; 13:1163768. PMID: 37324003
Background: The Spinnaker study evaluated survival outcomes and prognostic factors in patients with advanced non-small-cell lung cancer receiving first-line chemoimmunotherapy in the real world. This sub-analysis assessed the immunotherapy-related adverse...
5.
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
Anpalakhan S, Huddar P, Behrouzi R, Signori A, Cave J, Comins C, et al.
Int J Mol Sci . 2023 Jan; 24(2). PMID: 36675262
GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10−20%. GCSF has...
6.
Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)
Conway R, Symonds J, Walton D, Probets J, Comins C, Stadon L, et al.
BMJ Open . 2022 Nov; 12(11):e060850. PMID: 36357003
Introduction: Mesothelioma is a heterogeneous disease that can be challenging to monitor and prognosticate. ASSESS-meso is a multicentre, prospective, longitudinal observational cohort study of patients with mesothelioma. The primary aim...
7.
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer
Bahl A, Wilson W, Ball J, Renninson E, Dubey S, Bravo A, et al.
Breast . 2022 Oct; 66:69-76. PMID: 36194950
Background: Paclitaxel is commonly used as first-line chemotherapy for HER2-negative metastatic breast cancer (MBC) patients. However, with response rates of 21.5-53.7% and significant risk of peripheral neuropathy, there is need...
8.
A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology
Bibby A, Zahan-Evans N, Keenan E, Comins C, Harvey J, Day H, et al.
Pilot Feasibility Stud . 2022 Sep; 8(1):196. PMID: 36057634
Background: Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy with a poor prognosis. Systemic immunotherapy is an effective frontline treatment for MPM, and there is a scientific rationale supporting...
9.
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study
Banna G, Cantale O, Muthuramalingam S, Cave J, Comins C, Cortellini A, et al.
Int Immunopharmacol . 2022 Jul; 110:108985. PMID: 35777264
Background: Efficacy outcomes and prognostic factors of real-world patients with advanced non-small cell lung cancer (aNSCLC) treated with first-line chemoimmunotherapy are still limited. Patients And Methods: In the retrospective Spinnaker...
10.
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Cortellini A, Ricciuti B, Vaz V, Soldato D, Alessi J, DallOlio F, et al.
J Immunother Cancer . 2022 Feb; 10(2). PMID: 35173031
Introduction: It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung...